Omeprazole, lansoprazole and pantoprazole had no effect on blood pressure and electrocardiogram of anesthetized rat

Pharmacological Research

Volumn 58, Issue 1, 2008, Pages 65-71

  Yenişehirli, Aydan ^a   Naseri, Erdinç ^b  

^a GAZIOSMANPASA UNIVERSITY   (Turkey)

^b MEDICAL PARK HOSPITAL   (Turkey)

Author keywords

Blood pressure; Electrocardiogram; Lansoprazole; Omeprazole; Pantoprazole

Indexed keywords

HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; LANSOPRAZOLE; OMEPRAZOLE; OUABAIN; PANTOPRAZOLE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; CONCENTRATION RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG PROTEIN BINDING; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; HEART ATRIUM MUSCLE; HUMAN; HUMAN TISSUE; INOTROPISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPRODUCIBILITY; TENSION; WISTAR RAT;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANESTHESIA; ANIMALS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; ELECTROCARDIOGRAPHY; FEMALE; H(+)-K(+)-EXCHANGING ATPASE; HEART ATRIA; HEART RATE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MYOCARDIAL CONTRACTION; OMEPRAZOLE; PROTON PUMP INHIBITORS; RATS; RATS, WISTAR;

EID: 50649088586     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2008.06.012     Document Type: Article

References (32)

1. Zinchuk V.S., Koyabashi T., Garcia S., and Seguchi H. Biochemical properties and cytochemical localization of ouabain-insensitive, potassium-dependent p-nitrophemylphosphatase activity in rat atrial myocytes. J Histochem 45 (1997) 177-187
2. + exchange system in guinea pig myocardium. Jpn Heart J 40 (1999) 351-364
3. +-ATPase in the rat heart. Acta Physiol Scand 179 (2003) 251-262
4. Yenişehirli A., and Onur R. Positive inotropic and negative chronotropic effects of proton pump inhibitors in isolated rat atrium. Eur J Pharmacol 519 (2005) 259-266
5. Schillinger W., Teucher N., Sossalla S., Kettlewell S., Werner C., Raddatz D., et al. Negative inotropy of the gastric proton pump inhibitor pantoprazole in myocardium from humans and rabbits: evaluation of mechanisms. Circulation 116 (2007) 57-66
6. +-ATPase. Am J Physiol 272 (1997) H869-H874
7. +-ATPase in vascular smooth muscle cells. Am J Physiol 262 (1992) H1955-H1958
8. Kelicen P., Pekiner C., Sarioglu Y., and Uma S. Omeprazole-induced relaxation in rat aorta is partly dependent on endothelium. Pharmacol Res 46 (2002) 321-323
9. +-ATPase inhibitor, on rat aortic rings. Gen Pharmacol 27 (1996) 117-121
10. Sarioglu Y., Yildirim S., Utkan T., Yildirim M.K., and Uma S. Evidence of relaxant effect of omeprazole in rabbit corpus cavernosum, in vitro. Life Sci 66 (2000) 1411-1421
11. +-ATPase inhibitor SCH 28080. J Pharm Pharmacol 52 (2000) 857-862
12. Naseri E., and Yenisehirli A. Proton pump inhibitors omeprazole and lansoprazole induce relaxation of isolated human arteries. Eur J Pharmacol 531 (2006) 226-231
13. Waynforth H.B., and Flecknell P.A. Methods of obtaining body fluids. Experimental and surgical techniques in the rat. 2nd ed. (1992), Academic Press, London, UK pp. 68-87
14. Lehmann H.U., Hochrein H., Witt E., and Mies H.W. Hemodynamic effects of calcium antagonists. Hypertension 5 (1983) II66-II73
15. Cederberg C., Andersson T., and Skanberg I. Omeprazole: pharmacokinetics and metabolism in man. Scand J Gastroenterol Suppl 166 (1989) 33-42
16. Landes B.D., Petite J.P., and Flouvat B. Clinical pharmacokinetics of lansoprazole. Clin Pharmacokinet 28 (1995) 458-470
17. Huber R., Hartmann M., Bliesath H., Lühmann R., Steinijans V.W., and Zech K. Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther 34 (1996) S7-16
18. Lee D.Y., Shin H.S., Lee I., and Lee M.G. Pharmacokinetics of omeprazole in rats with water deprivation for 72 h. Biopharm Drug Dispos 27 (2006) 361-370
19. Xie Z., Zhang Y., Xu H., and Zhong D. Pharmacokinetic differences between pantoprazole enantiomers in rats. Pharm Res 22 (2005) 1678-1684
20. Kemi O.J., Arbo I., Hoydal M.A., Loennechen J.P., Wisloff U., Smith G.L., et al. Reduced pH and contractility in failing rat cardiomyocytes. Acta Physiol 188 (2006) 185-193
21. +)-adenosine triphosphatase by the proton pump inhibitor AG-1749. J Pharmacol Exp Ther 248 (1989) 799-805
22. Wallmark B., Jaresten B.M., Larsson H., Ryberg B., Brandstrom A., and Fellenius E. Differentiation among inhibitory actions of omeprazole, cimetidine, and SCN-on gastric acid secretion. Am J Physiol 245 (1983) G64-71
23. Ravens U., Gath J., al Hussaini M., and Himmel H. Mechanical restitution in atrial muscle from human and rat hearts: effects of agents that modify sarcoplasmic reticulum function. Pharmacol Toxicol 81 (1997) 97-104
24. 2+ exchanger in mammalian cardiac myocytes. J Physiol 488 (1995) 623-631
25. Bers D.M. Excitation-contraction coupling and cardiac contractile force. 2nd ed. (2001), Kluwer Academic Publishers, Dordrecht, Netherlands pp. 57-63
26. +-ATPase inhibitors decreased contractile responses of isolated rat vas deferens. Pharmacol Res 54 (2006) 397-405
27. Yildirim K., Sarioglu Y., Kaya T., Cetin A., and Yildirim S. Inhibitor effect of omeprazole in isolated human myometrial smooth muscle. Life Sci 69 (2001) 435-442
28. Aydin C., Sarac B., Koyuncu A., Yildirim S., Sen M., and Sarioglu Y. Relaxant effect of omeprazole and lansoprazole in guinea pig gall bladder muscle strips in vitro. J Gastroenterol 38 (2003) 765-771
29. Lorell B.H., Isoyama S., Grice W.N., Weinberg E.O., and Apstein C.S. Effects of ouabain and isoproterenol on left ventricular diastolic function during low-flow ischemia in isolated, blood-perfused rabbit hearts. Circ Res 63 (1988) 457-467
30. Bourdillon P.D., and Poole-Wilson P.A. The effects of verapamil, quiescence and cardioplegia on calcium exchange and mechanical function in ischemic rabbit myocardium. Circ Res 50 (1982) 360-368
31. Kim K.A., Shon J.H., Park J.Y., Yoon Y.R., Kim M.J., Yun D.H., et al. Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19. Clin Pharmacol Ther 72 (2002) 90-99
32. Pique J.M., Feu F., de Prada G., Rohss K., and Hasselgren G. Pharmacokinetics of omeprazole given by continuous intravenous infusion to patients with varying degrees of hepatic dysfunction. Clin Pharmacokinet 41 (2002) 999-1004